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Abstract
The prognostic role of MIB-1, BCL-2, VEGFR3, and CD31 expression was retrospectively evaluated in 224 renal
cell cancer (RCC) patients. The combination of high MIB-1/low BCL-2 was with poor survival compared with
low MIB-1/high BCL-2, and the combination of low VEGFR3/low CD31 was also associated with poor survival
compared with high VEGFR3/high CD31. These molecular expressions might be valuable in planning the
follow-up for RCC patients.
Objectives: The aim of this study was to evaluate the expression of MIB-1, BCL-2, VEGFR3, and CD31 and their
associations with long-term survival in patients with renal cell cancer (RCC). Patients and methods: This study
consisted of 224 RCC patients who underwent radical nephrectomy from 1985 to 1995. Follow-up continued for up to
over 20 years. MIB-1 and BCL-2 expression were analyzed alone, and additionally, the expression of MIB-1, BCL-2,
VEGFR3, and CD31 were combined in pairs using the following groups: low/low, low/high, high/low, and high/high.
Results: Low BCL-2 expression (hazard ratio [HR], 2.16; 95% conﬁdence interval [CI], 1.42-3.31; P < .001 compared
with high BCL-2 in univariate analysis) and high MIB-1 expression (HR, 2.05; 95% CI, 1.32-3.19; P ¼ .001 in multi-
variate analysis) were found to associate for poorer survival in RCC. In multivariate analysis, the combination of high
MIB-1/low BCL-2 was associated with poor survival compared with low MIB-1/high BCL-2 (HR, 3.20; 95% CI,
1.66-6.17; P ¼ .001), and the combination of low VEGFR3/high CD31 was associated with poor survival (HR, 2.48;
95% CI, 1.29-4.78; P ¼ .007) compared with high VEGFR3/high CD31. Conclusions: Compared with high BCL-2
expression in combination with low or high MIB-1, VEGFR3, or CD31 expression, low BCL-2 expression in combi-
nation with low or high MIB-1, VEGFR3, or CD31 expression has poorer survival in the long-term follow-up of patients
with RCC. Analysis of MIB-1, BCL-2, VEGFR3, and CD31 expression might be a useful additional marker to tailor the
follow-up of RCC patients.
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The most powerful prognostic factors for patients with localized
renal cell cancer (RCC) remain tumor stage, tumor grade, and
clinical variables such as performance status and presence or absence
of symptoms, and serum markers are used to determine the prog-
nosis of patients with metastatic RCC (mRCC).1-3 Previously,
several possible immunochemical markers have been studied to
predict the survival of patients with RCC, but none has attained
status as an independent prognostic marker.4-10
Vascular endothelial growth factor receptor 3 (VEGFR3) is
important for lymphangiogenesis in normal situations, and it is alsoBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MIB-1, BCL-2, VEGFR3 and CD31 as Prognosis Factors in RCCactivated in cancer and inﬂammation.11 It maintains both angio-
genesis and the lymphatic system, and therefore, it is considered an
interesting therapeutic target.12 Marked decreased VEGFR3 plasma
levels have been shown in patients with RCC after treatment with
multi-targeted tyrosine kinase inhibitor compared with stable or
progressive mRCC.13 Studies of VEGFR3 expression and its asso-
ciation with tumor stage, grade, and survival in patients with RCC
have shown conﬂicting results.7,9,14,15
CD31 is a member of an immunoglobulin superfamily of cell
adhesion molecules that are expressed on the surfaces of several
blood and endothelial cells.16,17 Higher expression of CD31 has
been associated with a lower tumor grade and better survival in
patients with RCC,5 and our previous study also showed an asso-
ciation between CD31 expression and survival but not tumor grade
or stage.9 Microvessel density has shown to correlate negatively to
prognosis in at least RCC studies.18-20 In addition, CD31 expres-
sion is found to associate with undifferentiated microvessels.21
MIB-1 is a well-known cell proliferation marker, while BCL-2 is
a marker of cell death.22,23 The expression of these markers has been
studied in patients with RCC. Higher MIB-1 expression was found
to be independently associated with poorer survival and with a
recurrence in these patients.4,24 Low BCL-2 expression was asso-
ciated with a higher tumor stage and a poorer prognosis in patients
with RCC.6 On the contrary, 2 studies did not ﬁnd association with
BCL-2 expression and a prognosis in RCC.8,25
Although the all markers mentioned above have been studied, none
has been identiﬁed as an independent prognostic factor. Therefore, the
aim of this study was to explore VEGFR3, CD31,MIB-1, and BCL-2
expression separately and in combination and to determine their
associations with long-term survival in patients with RCC.
Patients and Methods
Patient Population
This study included patients with RCC who underwent
nephrectomy from 1985 to 1995. The surgeries were performed at
Tampere University Hospital or at Tampere Hospital, Tampere,
Finland. All of the tumor samples were reclassiﬁed and re-evaluated
using the Heidelberg classiﬁcation and Fuhrman grading system26,27
by an experienced uropathologist (P.K.). A total of 202 (90.2%)
clear cell renal cell carcinoma (ccRCC), 12 (5.4%) papillary RCC
(pRCC), 5 (2.2%) chromophobe RCC, 2 sarcomatoid RCC
(0.9%), and 1 (0.4%) unclassiﬁed RCC were included in this study.
The tumor samples were classiﬁed as Fuhrman grade 1 to 2
(22; 9.8%), grade 3 (114; 50.9%), and grade 4 (88; 39.3%).
Clinical stage was assessed according to the TNM 2002 Classiﬁ-
cation of Malignant Tumors,28 and 79 (35.3%), 43 (19.2%), 61
(27.2%), and 39 (17.4%) of patients with RCC were TNM stages
1, 2, 3, and 4, respectively. The patients’ basic characteristics are
described in a table in our previous study.9
Due to poor immunostaining, 13 (5.8%) patients in the MIB-1
group, 3 (1.3%) in the BCL-2 group, 15 (6.7%) in the MIB-1/
BCL-2 group, 21 (9.4%) in the MIB-1/VEGFR3 group, 21
(9.4%) in the MIB-1/CD31 group, 15 (6.7%) in the BCL-2/CD31
group, and 14 (6.3%) in the VEGFR3/CD31 group were excluded
from the analyses.
After surgery, the patients’ follow-up and treatment were per-
formed according to standard clinical practice at that time. The- Clinical Genitourinary Cancer August 2016median follow-up time was 5.4 years, with a range of 0 to 21.7
years. Tampere University Hospital and the National Board of
Medicolegal Affairs approved the research protocol and use of the
tumor samples.
Immunostainings
Sections were deparafﬁnized, and antigen retrieval was achieved
by heating the sections in a microwave oven for 2  7 minutes in 10
mM tris/10 mM ethylenediaminetetraacetic acid (pH 9.0). For acid
Ki-67 antigen immunostaining, the monoclonal antibody MIB-1
(IgG1, Immuno-tech S. A., Mareille, France) was used at 1:110
dilution. Counterstaining was accomplished using 0.4% ethyl green
in acetate buffer. The staining of MIB-1 was evaluated by visual
estimation and by using a computer-assisted image analysis system
(CAS-200 Software; Becton Dickinson, Parsippany, NJ, USA). The
MIB-1 index was deﬁned as the percent of cells with immunopo-
sitivity in the nuclei. We ﬁrst evaluated patients between 1990 and
1995 by visual estimation; only deﬁnitely brown nuclei were
recorded as positive, and the same samples were evaluated using a
CAS-200. Spearman’s correlation between the visual estimation and
CAS-200 software was excellent (0.826; P < .001). Samples from
patients seen between 1985 and 1990 were analyzed by CAS-200,
and the results of computer-assisted image analysis were used for
statistical analysis.
Monoclonal mouse antihuman BCL-2 oncoprotein clone 124
(Dako, Glostrup, Denmark) was used at 1:60 dilution. Sections
were slightly counterstained by hematoxylin, and staining for
BCL-2 was analyzed semiquantitatively. Stainings were quantitated
by intensity (0-3) and the percent area of expression (0%-100%)
and by multiplying these ﬁgures to obtain staining scores (0-300).
Immunohistochemistry for CD31 (1:200, Novocastra Labora-
tories Ltd, Newcastle upon Tyne, UK) was performed on formalin-
ﬁxed, parafﬁn-embedded tissue sections as a part of a tissue
microarray. Brieﬂy, the sections were deparafﬁnized with xylen and
rehydrated in graded alcohol, treated in an autoclave in 10 mmol/l
sodium citrate (pH 5.0) for 2 minutes, and washed with phosphate
buffered saline. Primary antibody was incubated at 4C overnight,
and antibody binding was detected by Vectastain ABC kit reagents
(Vector Laboratories, Burlingame, CA, USA). Diaminobenzidine
was used as the chromogen. The slides were counterstained with
hematoxylin and eosin, and mounted.
VEGFR-3 was stained with the 9D9 antibody (a mouse mAb
against the extracellular domain of human VEGFR-3; a kind gift
from Professor Kari Alitalo, Helsinki, Finland) at the concentration
of 10 m/L as described in detail previously.29
Microvessel density was quantiﬁed as the number of CD31-
positive or VEGFR-3-positive microvessels per high-power ﬁeld
at 250 (ﬁeld of view 0.407 mm2, including the whole tissue
microarray core) using a Leitz Laborlux 12 bright-ﬁeld microscope
(Leitz Wetzlar GmbH, Germany). Two ﬁelds with the highest
density of vessels were counted, and an average of 2 scores was
reported. Scoring was performed in a blinded manner. Specimens
were analyzed independently by two investigators.
Statistical Methods
Statistical analyses were performed using IBM SPSS Statistic for
Windows version 21.0 (IBM Corp, Amonk, NY, USA; released
Table 1 Cross-Tabulation of MIB-1/BCL-2 Expressions and
VEGFR3/CD31 Expressions
MIB-1/
BCL-2
VEGFR3/CD31
TotalHigh/High low/low High/low low/High
n (%) n (%) n (%) n (%) n (%)
Low/high 26 (13) 10 (5) 12 (6) 9 (4.5) 57 (28.5)
High/high 18 (9.0) 6 (3.0) 15 (7.5) 4 (2.0) 43 (21.5)
Low/low 12 (6.0) 13 (6.5) 13 (6.5) 7 (3.5) 45 (22.5)
High/low 10 (5.0) 6 (3.0) 19 (9.5) 20 (10.0) 55 (27.5)
Total 66 (33.0) 35 (17.5) 59 (29.5) 40 (20) 200 (100)
The results are indicated in both numbers and percent of cases, P ¼ .002 (Pearson c2 test)
Juha P. Virman et al2010). The differences between categorical variables were tested
using the Pearson c2 test. The Cox proportional hazards models
were used in age- and gender-adjusted univariate and multivariate
survival analyses. In the multivariate model, all dependent variables
were entered simultaneously into the model. Furthermore, survival
was analyzed using the Kaplan-Meier survival estimation method.
All P-values under 0.05 were considered statistically signiﬁcant.
Results
Clinical Characteristics
Our cohort included 132 men (58.9%) and 92 woman (41.1%).
The patients’ median age at the time of nephrectomy was 65 years
(interquartile range, 55.9-71.9 years), and the median survival time
was 5.6 years (interquartile range, 1.6-11.9 years).
MIB-1 Expression
Only one sample had negative staining; the remaining samples
had positive expression of MIB-1. The median MIB-1 expression
value was 1.36, and the highest expression value was 40.9. The
MIB-1 expression values were divided into low (< 1.36) and high
( 1.36), according to the median staining result. Approximately
half of the ccRCC cases (96 samples; 50.3%) showed low expres-
sion. Three (30%) papillary RCCs (pRCC) had low and 7 (70%)
had high expression. Four (80%) chromophobe RCCs had low and
1 (20%) had high expression. The single collecting duct tumor and
the single unclassiﬁed RCC showed high expression. One sarco-
matoid type of RCC showed low expression, and the other
exhibited high expression. There was no association between his-
tologic type of RCC and MIB-1 expression (low or high; P ¼ .38).
Low expression of MIB-1 was observed in 10 (45.5%) grade 1 to 2
tumors, and high expression was seen in 12 (54.5%); 55 (51.4%)
and 52 (48.6%) grade 3 tumors and 39 (47.6%) and 43 (52.4%)
grade 4 tumors showed low and high expression of MIB-1,
respectively. There was no association between low/high MIB-1
expression and tumor grade (P ¼ .81). For tumor stages 1, 2, 3,
and 4, the distribution of low/high MIB-1 expression was 43
(57.3%)/32 (42.7%), 23 (54.8%)/19 (45.2%), 23 (40.4%)/34
(59.6%), and 15 (41.7%)/21 (58.3%), respectively (P ¼ .19).
BCL-2 Expression
Seventy-ﬁve (33.9%) tumor samples had negative staining for
BCL-2. The median expression of BCL-2 was 30, and the highest
value was 300. BCL-2 staining was divided into low (0-30) and high
(31-300) expression groups, based on the median value. Immuno-
staining of BCL-2 in ccRCC showed no differences; 102 (51.3%)
samples had low and 97 (48.7%) had high expression. Ten (83.3%)
pRCC had high and 2 (16.7%) had low BCL-2 expression. Three
(60%) chromophobe RCCs had low and 2 (40%) had high
expression. Both sarcomatoid RCCs had low immunostaining, as
did the single unclassiﬁed RCC, and the single collecting duct RCC
had high immunostaining. Fisher exact test showed P ¼ .037 on
cross-tabulation between low/high BCL-2 expression and different
histological types of RCC. For tumor grades 1 to 2, 3, and 4, the
BCL-2 expression was low in 6 (28.6%), 49 (43.8%), and 56
(63.6%) cases and high in 15 (71.4%), 63 (56.3%), and 32
(36.4%) cases, respectively (P ¼ .002). Low expression was
observed in 30 (39.0%), 19 (43.2%), 37 (60.7%), and 25 (65.8%)tumor samples in tumor stages 1, 2, 3, and 4, respectively, and high
expression was observed in 47 (61.0%), 25 (58.8%), 24 (39.3%),
and 13 (34.2%) samples, respectively (P ¼ .011).
Expressions of VEGFR3 and CD31
The expression of VEGFR3 and CD31 and their distributions
with tumor grade and stage were presented in our previous study.9
Brieﬂy, neither VEGRF3 expressions nor CD31 expressions showed
association with tumor stage or grade.
Combinations of MIB-1, BCL-2, VEGFR3, and CD31
Expressions
The expressions of MIB-1, BCL-2, VEGFR3, and CD31 were
divided into two groups (low and high). MIB-1, BCL-2, and CD31
were categorized according to their median expression levels of 1.36,
30, and 18, respectively, as follows: MIB-1 low (< 1.35) and high
( 1.35); BCL-2 low (0-30) and high (30-300); and CD31 low
( 18) and high (> 18). VEGFR3 expression was divided into low
(no positive vessels) and high (positive vessels). The cross-tabulation
between MIB-1/BCL-2 expression and VEGFR3/CD31 expression
is described in Table 1.
Univariate Analysis
Age- and gender-adjusted univariate analysis showed associations
between tumor stage, grade, and expressions of MIB-1 and BCL-2
with survival; for stage 4 compared with stage 1 disease: hazard ratio
(HR), 13.8; 95% conﬁdence interval (CI), 7.18-26.7; P < .001; for
stage 3 compared with stage 1 disease: HR, 4.37; 95% CI, 2.29-
8.35; P < .01; for stage 2 compared with stage 1 disease: HR, 2.62;
95% CI, 1.27-5.41; P ¼ .007; for grade 4 compared with grades 1
to 2: HR, 9.31; 95% CI, 2.23-38.8; P ¼ .002; for grade 3
compared with grades 1 to 2: HR, 4.91; 95% CI, 1.18-20.4;
P < .001; for high MIB-1 compared with low MIB-1: HR, 1.76;
95% CI, 1.16-2.68; P ¼ .008; for low BCL-2 compared with high
BCL-2: HR, 2.16; 95% CI, 1.42-3.31; P < .001. Cox regression
univariate analysis was also performed for pairs of markers (MIB-1,
BCL-2, VEGFR3, and CD31) and all possible variations of their
expressions (low/low, low/high, high/low and high/high); the results
are summarized in Table 2. Every combination of MIB-1,
VEGFR3, or CD31 expression with high BCL-2 expression
showed statistically better survival compared with combinations
with low BCL-2 expression. All combinations of MIB-1/BCL-2
were signiﬁcantly associated with survival; for high MIB-1/highClinical Genitourinary Cancer August 2016 - e285
Table 2 Age- and Gender-Adjusted Univariate Associations of
MIB-1, BCL-2, VEGFR3, and CD31 Expressions
N
Age- and Gender-Adjusted
Univariate
HR [95% CI] P
MIB-1/BCL-2
Low/high 58 1.00
High/high 47 2.13 [1.10-4.12] .025
Low/low 45 3.02 [1.62-5.62] .001
High/low 59 3.51 [1.94-6.36] <.001
MIB-1/VEGFR3
Low/high 55 1.00
Low/low 48 1.65 [0.91-3.01] .10
High/low 46 1.87 [1.02-3.43] .042
High/high 54 2.36 [1.32-4.22] .004
MIB-1/CD31
Low/high 62 1.00
Low/low 41 1.45 [0.80-2.63] .22
High/low 59 1.83 [1.07-3.11] .026
High/high 41 2.14 [1.20-3.82] .01
BCL-2/VEGFR3
High/high 60 1.00
High/low 45 1.10 [0.57-2.13] .77
Low/low 52 2.37 [1.35-4.15] .003
Low/high 52 2.71 [1.55-4.76] <.001
BCL-2/CD31
High/high 62 1.00
High/low 44 0.91 [0.46-1.76] .78
Low/high 41 2.15 [1.21-3.83] .009
Low/low 62 2.38 [1.41-4.02] .001
VEGFR3/CD31
High/high 70 1.00
High/low 62 1.10 [0.65-1.88] .75
Low/high 35 2.02 [1.14-3.60] .017
Low/low 43 2.22 [1.29-3.82] .004
Cox regression models were used, showing results by hazard ratios (HR) with 95% conﬁdence
intervals (CI).
Table 3 Age- and Gender-Adjusted Multivariate Associations
of Tumor Grade, Tumor Stage, and Expressions of
MIB-1 and BCL-2
N
Age- and Gender-Adjusted
Multivariate
HR [95% CI] P
Grade
1-2 22 1.00
3 114 2.51 [0.59-10.69] .21
4 88 6.45 [1.50-27.8] .012
Stage
1 79 1.00
2 44 2.96 [1.40-6.24] .004
3 61 3.58 [1.81-7.08] <.001
4 39 14.51 [7.13-29.55] <.001
MIB-1
Low 104 1.00
High 107 2.05 [1.32-3.19] .001
BCL-2
High 110 1.00
Low 111 1.40 [0.91-2.21] .12
Cox regression models were used, showing results by hazard ratios (HR) with 95% conﬁdence
intervals (CI).
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e286BCL-2: HR, 2.13; 95% CI, 1.10-4.12; P ¼ .025; for low MIB-1/
low BCL-2: HR, 3.02; 95% CI, 1.62-5.62; P ¼ .001; for high
MIB-1/low BCL-2: HR, 3.51; 95% CI, 1.94-6.36; P < .001,
compared with low MIB-1/high BCL-2. The remaining combina-
tions showed no signiﬁcant association with survival. Univariate
analysis of VEGFR3 and CD31 expression with tumor stage and
grade showed that low CD31 expression had poorer prognosis in
RCC patients but VEGFR3 expression had no association with
survival in RCC. The results are described our previous study.9
Multivariate Analysis
Multivariate Cox hazard regression analysis was performed
including tumor grade, tumor stage, and expressions of MIB-1
and BCL-2 simultaneously into the model with age and gender,
described in Table 3. Statistically signiﬁcant combinations- Clinical Genitourinary Cancer August 2016MIB-1/BCL-2 and VEGFR3/CD31 in age- and gender-adjusted
univariate analyses were tested with tumor stage and grade in
multivariate analysis. Higher tumor stage showed poorer survival,
and the combination of MIB-1/BCL-2 almost reached statistically
signiﬁcant association in survival of all combinations; the results
are summarized in Table 4.
Kaplan-Meier Analysis
Kaplan-Meier (KM) survival analysis was used to illustrate MIB-1
and BCL-2 expression and the expression of the combinations
described above. Increased BCL-2 expression and low MIB-1
expression showed better survival in KM curves compared with
low BCL-2 and high MIB-1 expressions (Figures 1A and 1B).
Lower BCL-2 expression in combination with low or high MIB-1,
VEGFR3, or CD31 expression showed poorer survival compared
with any combinations with high BCL-2 expression. The plateau
phase, a time after diagnosis when patients have no RCC-related
mortality, was estimated by Kaplan-Meier survival curve analysis
and was found to be 1.2 years for low grade (1-2) tumors. For
higher tumor grades (3 and 4), the plateau occurred almost 10 years
later, at 12.4 and 9.9 years, respectively. For stages 1, 2, 3, and 4,
the plateau phases were reached within 4, 8.5, 12.4, and 9.9 years,
respectively. No RCC-related deaths were observed after 9.9 and
12.4 years in tumors with low and high MIB-1 expression and after
9.9 and 12.4 years in tumors with high and low BCL-2 expression,
respectively. Over half of patients having expression combinations
of low MIB-1/high BCL-2, low MIB-1/high VEGFR3, high BCL-2
and low/high VEGFR3, or high BCL-2 and low/high CD31 were
alive 10 years after nephrectomy. KM curves of the combinations of
MIB-1/BCL-2, VEGFR/CD31, and BCL-2/VEGFR3 expression
are shown in Figures 2A-C.
Table 4 Age- and Gender-Adjusted Multivariate Associations
of MIB-1/BCL-2 and VEGFR3/CD31 Expressions With
Stage and Grade
n
Age- and Gender-Adjusted
Multivariate
HR [95% CI] P
MIB-1/BCL-2
Low/high 57 1.00
Low/low 45 1.60 [0.83-3.08] .16
High/high 42 2.14 [1.07-4.29] .032
High/low 55 3.20 [1.66-6.17] .001
VEGFR3/CD31
High/high 66 1.00
Low/low 58 0.92 [0.52-1.63] .79
High/low 40 1.28 [0.70-2.43] .46
Low/high 35 2.48 [1.29-4.78] .007
Stage
1 67 1.00
2 40 2.60 [1.28-5.25] .008
3 57 2.58 [1.40-4.73] .002
4 35 8.85 [4.47-17.5] <.001
Grade
1-2 20 1.00
3 102 1.44 [0.48-4.24] .51
4 78 3.25 [1.09-9.73] .035
Cox regression models were used, showing results by hazard ratios (HR) with 95% conﬁdence
intervals (CI).
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In this study, we explored the expression of MIB-1, BCL-2,
VEGFR3, and CD31 and their associations with survival in patientsFigure 1 (A) Kaplan-Meier Curves for MIB-1 Expression (Low/High)with RCC. Our study consisted of 224 patients, for whom all tumor
samples were re-evaluated and reclassiﬁed by a qualiﬁed uropa-
thologist (P.K.). All data were collected directly from the original
medical records. The survival data were obtained from the Finnish
Cancer Registry; thus were very reliable.
Clinicians today have a better understanding of molecular
pathway abnormalities, histological subtypes, and new morpholog-
ical variants of RCC.30 The improved knowledge might aid in
the discovery of new treatments for patients with RCC.31,32 The
standard follow-up practice for patients with RCC is not clear and
has been debated in the literature, and the tendency is toward more
individual treatment and management of RCC. We urgently need
new molecular markers to plan these patients’ individual treatments
and follow-up.
In the present study, the expression of the proliferation markers
MIB-1 and BCL-2 alone and with the angiogenesis markers
VEGFR3 and CD31, and their associations with survival, was
explored in patients with RCC. We classiﬁed the expression of
MIB-1, BCL-2, VEGFR3, and CD31 into low and high expression
groups according to their immunostaining scores. High MIB-1
expression was associated with poorer disease-free survival and
overall survival in patients with RCC in a previous study.33
Similarly, our study showed that low MIB-1 expression was inde-
pendently associated with a better prognosis in these patients.
Higher BCL-2 expression in combination with any low or high
expression of MIB-1, VEGFR3, or CD31 showed better survival
compared with combinations with low BCL-2 expression. Previous
studies have also found that increased BCL-2 expression was
associated with a better prognosis for patients with RCC.6 Our
univariate analysis showed that a combination of the proliferation
marker MIB-1 and an anti-apoptosis marker BCL-2 had a statisti-
cally signiﬁcant association with survival in patients with RCC.
Anti-apoptotic proteins such as BCL-2 are often overexpressed in
cancer, while apoptotic proteins are deregulated.34 RCC is, in. (B) Kaplan-Meier Curves for BCL-2 Expression (Low/High)
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Figure 2 (A) Kaplan-Meier Curves for Combinations of MIB-1 and BCL-2 Expressions (Low/High). (B) Kaplan-Meier Curves for
Combinations of BCL-2 and CD31 Expressions (Low/High). (C) Kaplan-Meier Curves for Combinations of BCL-2 and VEGFR3
Expressions (Low/High)
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e288general, a highly vascular tumor, and angiogenesis is very important
for tumor growth and spread. Histological tumor necrosis is shown
to be associated with poorer survival in RCC.35 Overexpression of
BCL-2 was shown to prevent necrosis,36 which might be one of the
explanatory factors for the improved survival of patients with RCC
and higher BCL-2 expression. MIB-1 expression was also signiﬁ-
cantly associated with survival in multivariate analysis, in which the
classical prognostic factors of tumor stage and grade were also
included. Our previous study showed that higher CD31 expression
was associated with a better prognosis in patients with RCC
compared with low CD31 expression.9 This present study showed
that higher CD31 expression had no strong association with sur-
vival, whereas high BCL-2 had a strong association with better
survival with all combinations of MIB-1, VEGFR3, and CD31
expressions.
VEGFR3 is important for both angiogenesis and lymphatic
maintenance,12 whereas CD31 is involved in tissue regeneration,
and its expression has been shown in vascular tumors.16 This study
showed that the combination of high VEGFR3/high CD31 was
associated with a better prognosis compared with low VEGFR3/low
CD31. This may indicate that patients with better lymphangio-
genesis and active tissue regeneration have a better prognosis.
We also examined associations between combinations of MIB-1
and BCL-2 expression, which are related to cell growth and
apoptosis, and combinations of VEGFR3 and CD31 expression,
which are related to tumor angiogenesis. Cross-tabulation showed a
signiﬁcant association between them, as shown in Table 1. Distri-
butions were in the same line as survival analysis showed; however,
4.5% of cases with low MIB-1/high BCL-2, which was associated
with better survival, had low VEGFR3/high CD31, which was
associated with poorer survival; in addition, 5% of cases with high
MIB-1/low BCL-2, which was associated with a poorer prognosis,
had high VEGFR3/high CD31, which was associated with a better
prognosis. Based on these results, we cannot clearly indicate clear
associations between the expressions of these combinations of- Clinical Genitourinary Cancer August 2016factors; perhaps there are other factors of which we are not yet aware
that affect tumor growth, death, and tumor angiogenesis.
This present study included 224 consecutive patients whose
RCC was diagnosed from 1985 to 1995. During that time, radio-
logical examinations were performed less frequently than they are
currently. Over 50% of RCCs are currently detected incidentally.30
This might be the reason that our study population consisted of
only 22 (9.8%) patients with grade 1 or 2 tumor and 79 (35.3%)
patients with stage 1 tumor. Our study showed an association
between higher Bcl-2 expression and pRCC, but no association
between MIB-1 expression and histological type of RCC. This
might be explained by the fact that the majority histological type in
our study was ccRCC (90.2%) and this represents a higher pro-
portion than is generally found in RCC.26,37,38 Due to inadequate
immunostaining, we excluded 3 to 21 patients (1.3%-9.4%) from
the analyses. The excluded portion was, however, minor and
therefore had an insigniﬁcant effect on the results.
Our study showed that over 50% of patients with low MIB-1 or
high Bcl-2 expression were alive at the end of long-term follow-up.
The survival plateau was reached already after 1.2 years in patients
with grade 1 to 2 tumors, whereas for other grades and stages, the
MIB-1 and Bcl-2 expression groups’ plateaus were achieved between
8.5 and 12.4 years. Additionally, 50% of patients with low MIB/
high BCL-2, low MIB-1/high VEGFR3, high BCL-2 and low/high
VEGFR3, or high BCL-2 and low/high CD31expression survived
10 years after the diagnosis of RCC. These data showed that all
patients with RCC who were alive 10 years after nephrectomy had
an excellent prognosis. The follow-up guidelines of RCC have been
recently discussed in the literature.32 Smith et al. showed that nearly
one-third of RCC recurrences were missed when patients were
followed according to the American Urological Association or
National Comprehensive Cancer Network guidelines.39 New
molecular markers or their combinations might be needed to
improve the assessment of recurrence risk and to tailor treatment
and follow-up for patients with RCC. MIB-1, BCL-2, VEGFR3,
Juha P. Virman et aland CD31 might be useful for individual follow-up of patients with
RCC and should be tested in prospective trials.
Conclusion
These data showed that low BCL-2 alone or in any combination
with low or high MIB-1, VEGFR3, or CD31 expression was
associated with poorer survival in patients with RCC. Low MIB-1
expression was an independent predictor of better prognosis in
patients with RCC. Low VEGFR3/low CD31 expression was
associated with poor survival compared with high VEGFR3/high
CD31 expression. These markers might be useful for planning the
follow-up of patients with RCC.
Clinical Practice Points
 There are no molecular markers to predict survival in patients
with RCC. We evaluated the expressions of MIB-1, BCL-2,
VEGFR3, and CD31 and their role in the prognosis of RCC.
 This study showed that low MIB-1 and high BCL-2 expressions
were associated with improved survival in RCC.
 High VEGFR3/high CD31 expression showed better survival
compared with low VEGFR3/high CD31 expression.
 Molecular markers might be useful for planning patients’
follow-up.Disclosure
The authors have stated that they have no conﬂicts of interest.References
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